percp (Agilent technologies)
Structured Review
Percp, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 95/100, based on 964 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/percp/PerCP/custom%40pb40%4042531894
Average 95 stars, based on 964 article reviews
Images
Related Articles
Control:Article Title: EGFR-dependent delivery of phosphorylated IGFBP3 by cancer stem cells drives chemotherapy resistance in colorectal cancer. Article Snippet: with 2 μL Concentration Assay:Article Title: EGFR-dependent delivery of phosphorylated IGFBP3 by cancer stem cells drives chemotherapy resistance in colorectal cancer. Article Snippet: with 2 μL Cell Culture:Article Title: EGFR-dependent delivery of phosphorylated IGFBP3 by cancer stem cells drives chemotherapy resistance in colorectal cancer. Article Snippet: with 2 μL Flow Cytometry:Article Title: EGFR-dependent delivery of phosphorylated IGFBP3 by cancer stem cells drives chemotherapy resistance in colorectal cancer. Article Snippet: with 2 μL Centrifugation:Article Title: EGFR-dependent delivery of phosphorylated IGFBP3 by cancer stem cells drives chemotherapy resistance in colorectal cancer. Article Snippet: with 2 μL Cytometry:Article Title: EGFR-dependent delivery of phosphorylated IGFBP3 by cancer stem cells drives chemotherapy resistance in colorectal cancer. Article Snippet: with 2 μL FACS:Article Title: EGFR-dependent delivery of phosphorylated IGFBP3 by cancer stem cells drives chemotherapy resistance in colorectal cancer. Article Snippet: with 2 μL Software:Article Title: EGFR-dependent delivery of phosphorylated IGFBP3 by cancer stem cells drives chemotherapy resistance in colorectal cancer. Article Snippet: with 2 μL Fluorescence:Article Title: EGFR-dependent delivery of phosphorylated IGFBP3 by cancer stem cells drives chemotherapy resistance in colorectal cancer. Article Snippet: with 2 μL Enzyme-linked Immunosorbent Assay:Article Title: EGFR-dependent delivery of phosphorylated IGFBP3 by cancer stem cells drives chemotherapy resistance in colorectal cancer. Article Snippet: with 2 μL Suspension:Article Title: EGFR-dependent delivery of phosphorylated IGFBP3 by cancer stem cells drives chemotherapy resistance in colorectal cancer. Article Snippet: with 2 μL Cell Cycle Assay:Article Title: EGFR-dependent delivery of phosphorylated IGFBP3 by cancer stem cells drives chemotherapy resistance in colorectal cancer. Article Snippet: with 2 μL Incubation:Article Title: EGFR-dependent delivery of phosphorylated IGFBP3 by cancer stem cells drives chemotherapy resistance in colorectal cancer. Article Snippet: with 2 μL Staining:Article Title: EGFR-dependent delivery of phosphorylated IGFBP3 by cancer stem cells drives chemotherapy resistance in colorectal cancer. Article Snippet: with 2 μL Lysis:Article Title: EGFR-dependent delivery of phosphorylated IGFBP3 by cancer stem cells drives chemotherapy resistance in colorectal cancer. Article Snippet: with 2 μL |
